Drug Type Bispecific antibody |
Synonyms- |
Target |
Action inhibitors |
Mechanism IL-13 inhibitors(Interleukin-13 inhibitors), TSLP inhibitors(Thymic stromal lymphopoietin inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Mild asthma | Phase 1 | Australia | 03 Mar 2026 | |
| Moderate asthma | Phase 1 | Australia | 03 Mar 2026 | |
| Asthma | Preclinical | United States | 01 Jul 2025 | |
| Chronic sinusitis | Preclinical | United States | 01 Jul 2025 | |
| Dermatitis, Atopic | Preclinical | United States | 01 Jul 2025 |






